Adage Capital Partners Gp, L.L.C. 9 Meters Biopharma, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.21 - $0.32 $272,081 - $414,600	-1,295,627 Reduced 9.06%	13,000,000 $2.8 Million
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.64 $183,136 - $450,798	-704,373 Reduced 4.7%	14,295,627 $3.73 Million
Q2 2021 Aug 16, 2021	BUY	$1.04 - $1.5 $364,000 - $525,000	350,000 Added 2.39%	15,000,000 $16.5 Million
Q1 2021 May 17, 2021	BUY	$0.84 - $2.16 $1.39 Million - $3.56 Million	1,650,000 Added 12.69%	14,650,000 $17.1 Million
Q4 2020 Feb 16, 2021	BUY	$0.65 - $1.11 $8.45 Million - $14.4 Million	13,000,000 New	13,000,000 $11.2 Million

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.